Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Neuroectodermal Tumors, Primitive × Temozolomide × Clear all

Phase

Status

Sponsor Class

OTHER 5 NIH 3 NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Central Nervous System Neoplasms 23 Glioblastoma 13 Astrocytoma 13 Oligodendroglioma 11 Gliosarcoma 11 Brain Neoplasms 10 Glioma 9 Spinal Cord Neoplasms 3 Ependymoma 3 Neuroblastoma 2 Neoplasm Metastasis 2 Melanoma 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Somatostatinoma 1 Sarcoma, Ewing 1 Neurotoxicity Syndromes 1 Neuroectodermal Tumors, Primitive 1 Medulloblastoma 1 Lymphoma 1 Gastrointestinal Stromal Tumors 1 Carcinoma, Neuroendocrine 1 Biliary Tract Neoplasms 1 Adenoma, Islet Cell 1 Adenocarcinoma, Bronchiolo-Alveolar 1 Adenocarcinoma of Lung 1

Interventions

azurin (50-77) 1 Temozolomide 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02358356 2022-07-05

CONTROL NETS

Australasian Gastro-Intestinal Trials Group

Phase 2 Completed

Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon ⚡